Close Menu

NEW YORK – Ambry Genetics announced on Monday that its +RNAinsight combined DNA-RNA genetic test for hereditary cancer syndromes has received approval from the New York State Clinical Laboratory Evaluation Program (CLEP).

The +RNAinsight test, which was launched in October, enables clinicians to conduct both DNA and RNA genetic testing at the same time, with the aim of returning more specific results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.